Reports of fatalities through cardiovascular toxic effects after regional anesthesia with bupivacaine in the late 1970s ([@b1]) triggered pharmacological research that emphasized the selective behavior of the two enantiomers of racemic bupivacaine, ie, levo- or S (−)-bupivacaine and dextro- or R (+)-bupivacaine, once in contact with biological receptors in the body. Levo-enatiomer appeared to have a safer pharmacological profile than its dextro-partner. Efforts were intensified to synthesize a pure S (−)-bupivacaine enantiomer, and Chirocaine^®^ (levobupivacaine) Injection (Darwin Discovery Ltd., distributed by [@b79]. Ropivacaine (Naropin^®^ (ropivacaine HCL) injection, Astra Zeneca Int., distributed by Abraxis BioScience, California, US), another pure S (−)-enantiomer, became also available as an alternative to the racemic mixture for regional anesthesia. This review discusses the pharmacological rationale behind the safer profile of levobupivacaine, and its up-to-date use in anesthesia. The descriptors bupivacaine, levobupivacaine and dextrobupivacaine are used for the racemic mixture and its selective enatiomers, respectively.

Pharmacodynamic foundation of the lesser cardiovascular and central nervous toxicity of levobupivacaine
=======================================================================================================

In common to all local anesthetics levobupivacaine reversibly blocks the transmission of action potential in sensory, motor and sympathetic nervous fibers by inhibiting the passage of sodium through voltage-sensitive ion channels in the neuronal membrane. Whereas the inhibitory action is intended to be localized at the site of administration, excessive doses or accidental intravascular injection may lead to activity at the level of other ion channels in excitable tissues followed by unwanted central nervous and cardiovascular adverse effects. The current pharmacodynamic evidence from animal and human studies suggests that levobupivacaine has a potentially greater margin of safety than the racemic bupivacaine.

Cardiovascular toxicity
=======================

Levobupivacaine demonstrated less affinity and strength of inhibitory effect onto the inactivated state of cardiac sodium channels than the racemic parent or dextrobupivacaine in in vitro animal tissue experimental studies ([@b89]; [@b88]). It also showed less depressant effect on the atrioventricular conduction ([@b43]) and QRS complex duration ([@b63]), and provoked less impairment of the contractile function of the isolated animal heart ([@b83]). Levobupivacaine was also less potent in blocking cloned human heart sodium and potassium channels ([@b87]; [@b67]).

Similarly, in vivo animal studies showed that the cardio-toxic dose of intravenous bupivacaine and its pure S (−)-enantiomers followed the order ropivacaine \>levobupivacaine \>bupivacaine ([@b46]; [@b69]). The estimated mean (standard deviation) fatal dose through severe arrhythmias after intravenous administration of levobupivacaine in sheep is 277 (51) mg, which is significantly larger than the fatal dose of bupivacaine of 156 (31) mg ([@b27]). In regards to the reversibility of cardio-toxic effects, evidence is less clear. It was shown in anaesthetized open chest dogs receiving a continuous infusion of local anesthetic until cardiovascular collapse that animals receiving bupivacaine were more likely to have a fatal outcome than animals receiving levobupivacaine and ropivacaine but the differences were not significant ([@b45]). In another study, there was no difference in the number of successfully resuscitated anaesthetized rats after the administration of bupivacaine, levobupivacaine or ropivacaine ([@b69]). However, less epinephrine was required for the successful resuscitation of rats receiving ropivacaine than those receiving levobupivacaine or bupivacaine.

Central nervous toxicity
========================

The uptake of bupivacaine by the central nervous cells is also enantio-selective. For example, experiments in anesthetized rats receiving arrhythmogenic intravenous doses of levobupivacaine or dextrobupivacaine showed a less rapid blockage of the cell firing in the nucleus tractus solitarius after levobupivacaine than after dextrobupivacaine ([@b34]). All animals receiving dextrobupivacaine developed apnea and died whereas those receiving levobupivacaine continued to breathe and all but two survived.

The mean (standard deviation) convulsive dose after intravenous levobupivacaine in conscious sheep is 103 (18) mg, significantly higher than the convulsive dose of bupivacaine of only 85 (11) mg ([@b46]). The convulsive dose of ropivacaine is 155 mg ([@b66]). The susceptibility for seizure activity after intoxication with levobupivacaine and ropivacaine is 1.5--2.5 times less than that after racemic bupivacaine ([@b44]).

In human volunteers studies, the mean dose of intravenous levobupivacaine and bupivacaine associated with central nervous system symptoms was similar, ie, 56--68 mg and 48--65 mg, respectively ([@b3]; [@b68]). At this similar dose, levobupivacaine showed significantly less myocardial contractility and atrio-ventricular conduction depressant effect than bupivacaine.

Pharmacokinetic foundation of the lesser cardiovascular and central nervous toxicity of levobupivacaine
=======================================================================================================

In human volunteers studies, the volume of distribution and overall clearance of levobupivacaine was significantly lower than that of dextrobupivacaine ([@b13]). Nevertheless, the pharmacokinetics of the unbound fraction of levobupivacaine accounts for its less toxicity. The unbound fraction of levobupivacaine was significantly lower than that of unbound dextrobupivacaine because of its increased protein-binding affinity. Together with a higher clearance of the unbound levobupivacaine, this explains the shorter elimination half-life of levobupivacaine while the volume of distribution of both unbound drug was similar ([@b13]). An increase in postoperative levels of alpha-1-glycoprotein ([@b33]) that binds large amounts of levobupivacaine, may further explain the lack of toxicity even when large volumes of racemic bupivacaine were administered in clinical studies ([@b5]; [@b6]; [@b62]). No clinical signs of cardio-vascular toxicity were demonstrated despite consistent significantly higher total plasma concentrations of levobupivacaine vs dextrobupivacaine.

Various factors such as site of administration, duration of continuous infusion and/or addition of agents with vasomotor effect may influence the degree of systemic uptake of levobupivacaine. For example, the administration of levobupivacaine in paravertebral anesthesia and analgesia was characterized by rapid absorption after bolus injection and progressive accumulation after continuous infusion with maximum plasma concentrations at 24 hours ([@b12]). A similar rapid absorption from the paravertebral space was reported in other studies ([@b5]; [@b72]), fortunately without clinical signs of toxicity. The addition of epinephrine decreased peak plasma levels of levobupivacaine after epidural analgesia ([@b52]). In research carried out by our own group, the addition of clonidine to low concentration levobupivacaine (0.05%) was followed by a more erratic pattern of systemic absorption of levobupivacaine from the paravertebral space, which, although did not reach toxic levels, may raise concerns of increased potential for toxicity due to the combined vasodilator effects of the two drugs ([@b12]).

Clinical toxicity and tolerability
==================================

Regardless of the type of regional blockade with levobupivacaine, 78% of patients may experience at least one adverse effect such as hypotension (20%), nausea (12%), postoperative pain (18%), fever (17%), vomiting (14%), anemia (12%), pruritus (9%), back pain (8%), headache (7%), constipation (7%), dizziness (6%) and fetal distress (5%) ([@b79]). The incidence of adverse events with levobupivacaine was similar to that after bupivacaine in comparative trials.

The early clinical presentation of toxicity after levobupivacaine appears to consist of central nervous symptoms (disorientation, drowsiness, slurred speech), which may culminate with tonic-clonic seizures in some cases ([@b50]; [@b75]; [@b48]; [@b32]; [@b8]). These excitatory symptoms are generally self-limiting, or respond easily to anticonvulsant treatment. In anaesthetized patients, however, sudden cardiovascular collapse may emerge which appears to be relatively easily treated with moderate doses of sympathomimetics ([@b80]).

Levobupivacaine in current regional anesthesia practice for surgery
===================================================================

Spinal anesthesia
-----------------

Because of the small doses of local anesthetic used for subarachnoid administration, systemic toxicity is not a problem. Not surprisingly therefore, bupivacaine remains the most widely and cost-efficient long acting local anesthetic used in spinal anesthesia. A surgical sensory and motor block of similar characteristics and recovery over equal dose ranges of levobupivacaine and bupivacaine was demonstrated in healthy volunteers ([@b2]) and confirmed in surgical patients ([@b42]; [@b55]; [@b22]; [@b40]) ([Table 1](#tbl1){ref-type="table"}). The regression of motor block was significantly more rapid after levobupivacaine and ropivacaine than bupivacaine in a study by Casati and colleagues, which may be advantageous for early ambulation after day-case surgery ([@b22]).

###### 

Summary of patient studies that used levobupivacaine in spinal anesthesia

  Reference   Dose/concentration                             No. of patients   Type of surgery               Onset time of sensory block, mean (SD) or median (range), min   Maximum (range) sensory dermatome level   Duration of sensory block mean (SD) or median (range), min   Complete sensory block (% patients)   Onset time of motor block mean (SD) or median (range), min   Duration of motor block mean (SD) or median (range), min   Complete motor block (% patients)   Outcome (time to void), min
  ----------- ---------------------------------------------- ----------------- ----------------------------- --------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------ ------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------- ----------------------------------- ------------------------------------------------
  [@b10]      3 mL levobupivacaine 0.5%                      20                Varicose veins surgery        2 (2--10)                                                       T8 (T4--L3)                               388 (295--478)                                               90%                                   5 (2--10)                                                    266 (170--415)                                             95%                                 
  [@b42]      3.5 mL levobupivacaine 0.5%                    39                Hip surgery                   11 (6)                                                          T8                                        228 (77)                                                     100%                                  10 (7)                                                       280 (84)                                                   100%                                
              3.5 mL bupivacaine 0.5%                        40                                              13 (8)                                                          T8                                        237 (88)                                                     100%                                  9 (7)                                                        284 (80)                                                   100%                                
  [@b55]      2.6 mL levobupivacine 0.5%                     24                Urological surgery            10 (6)                                                          T7 (T3--T10)                                                                                                                                                                                                                                                         37%                                 
              2.6 mL bupivacaine 0.5%                        26                                              8 (4)                                                           T8 (T3--T10)                                                                                                                                                                                                                                                         49%                                 
  [@b7]       10 mg levobupivacaine                          20                Ambulatory knee arthroscopy   8 (6)                                                           T10 (C8--L1)                              173 (47)                                                     97%                                                                                                137 (40)                                                   74%                                 284 (57)
              15 mg ropivacaine                              20                                              7 (4)                                                           T11 (T3--L2)                              167 (49)                                                     97%                                                                                                142 (44)                                                   85%                                 285 (65)
              60 mg lidocaine                                20                                              6 (4)                                                           T10 (T3--L2)                              145 (30)[a](#tf1-1){ref-type="table-fn"}                     94%                                                                                                127 (29) Regression at 180 min                             85%                                 245 (65)[a](#tf1-1){ref-type="table-fn"}
  [@b22]      8 mg hyperbaric levobupivacaine 0.5%           20                Inguinal hernia repair        10 (5)                                                          T8 (T12--L5)                              210 (63)                                                     100%                                                                                               84%                                                        100%                                255 (58)
              8 mg hyperbaric bupivacaine 0.5%               20                                              10 (4)                                                          T6 (T12--L5)                              190 (51)                                                     100%                                                                                               55%[c](#tf1-3){ref-type="table-fn"}                        100%                                298 (68)
              12 mg ropivacaine 0.5%                         20                                              10 (6)                                                          T5 (T10--L2)                              166 (42)[b](#tf1-2){ref-type="table-fn"}                     100%                                                                                               95%                                                        100%                                302 (48)
  [@b18]      7.5 mg hyperbaric levobupivacaine 0.5%         30                Ambulatory knee arthroscopy   11 (10--16)                                                     T8 (T7--9)                                162 (148--201)                                               100%                                                                                                                                                                                              238 (221--276)
              5 mg hyperbaric levobupivacaine 0.5%           30                                              10 (9--12)                                                      T10 (T7--10)                              150 (136--185)                                               97%                                                                                                                                                                                               190 (181--247)[e](#tf1-5){ref-type="table-fn"}
              7.5 mg hyperbaric ropivacaine 0.5%             31                                              10 (9--13)                                                      T9 (T8-L1)                                135 (126--154)[d](#tf1-4){ref-type="table-fn"}               97%                                                                                                                                                                                               189 (126--154)[e](#tf1-5){ref-type="table-fn"}
  [@b56]      2.6 mL levobupivacaine 0.5%                    25                Urological surgery            8 (4.5)                                                         T6 (T3--T10)                                                                                                                                                                                                                                                         96%                                 
              2.3 mL levobupivacaine 0.5% + 15 μg fentanyl   25                                              7.4 (2.8)                                                       T7 (T4--T10)                                                                                                                                                                                                                                                         84%                                 
  [@b40]      3 mL levobupivacaine 0.5%                      29                Hip or knee                   12 (6)                                                          T8 (4--12)                                391 (96)                                                     69%                                   11 (6)                                                       256 (86)                                                   86%                                 
              3 mL bupivacaine 0.5%                          30                replacement surgery           9 (5)                                                           T8 (4--12)                                381 (105)                                                    82%                                   8 (4)                                                        245 (86)                                                   100%                                

p \< 0.05 lidocaine vs levobupivacaine and ropivacaine;

p \< 0.05 ropivacaine vs levobupivacaine and bupivacaine;

p \< 0.05 bupivacaine vs levobupivacaine and ropivacaine;

p \< 0.05 ropivacaine vs levobupivacaine 7.5 mg;

p \< 0.05 ropivacaine and levobupivacaine 5 mg vs levobupivacaine 7.5 mg.

Traditionally, the dose of levobupivacaine used for spinal anesthesia is 15 mg. This dose provides an adequate sensory and motor block for most surgical procedures lasting approximate 6.5 hours ([@b10]). An up-and-down sequential design study recommends a minimum effective local anesthetic dose (MLAD) of levobupivacaine 11.7 mg ([@b81]). Smaller doses (ie, 5--10 mg) have been used in ambulatory surgery, and allow a more rapid recovery and subsequent discharge home ([@b7], [@b18]). The addition of fentanyl 15 μg demonstrate a sparing effect on the requirement of levobupivacaine while maintaining excellent clinical efficacy with less hemodynamic variation ([@b56]) ([Table 1](#tbl1){ref-type="table"}).

Epidural anesthesia and analgesia
---------------------------------

[Table 2](#tbl2){ref-type="table"} presents a summary of studies regarding the use of levobupivacaine in epidural anesthesia and analgesia for surgery. The onset of sensory block (8--30 min), maximum upper spread (T7-T8 after L2-L3 or L3-L4 lumbar injection) and duration (4--6 hours) are similar after equal doses of levobupivacaine and bupivacaine (15 mL 0.5%) ([@b30]; [@b23]). The onset of motor block is slower with levobupivacaine ([@b51]), and its quality follows the rank of order bupivacaine \>levobupivacaine \>ropivacaine ([@b30]; [@b51]; [@b23]; [@b71]). The duration of motor block, however, appears to be similar ([@b30]; [@b51]; [@b71]). Increasing the concentration of levobupivacaine (ie, 15 mL 0.75% vs 0.5%) prolongs the duration of sensory and motor block without increasing the incidence of adverse side effects ([@b30]). However increasing both volume and concentration to 20 mL levobupivacaine 0.75% is associated with a high incidence of hypotension (82%) and delayed block regression ([@b51]).

###### 

Summary of research investigating the quality of surgical epidural block after levobupivacaine

  Reference   Dose/concentration and technique                                                                         No. of patients   Type of surgery           Onset time to surgical block, mean (SD) or median (range), min   Maximum sensory dermatome level   Duration of sensory block; mean (SD) or median (range), min or h   Onset time of motor block; mean (SD) or median (range), min   Duration of motor block; mean (SD or range), min or h   Completeness of motor block (% patients)   Adverse events(arterial hypotension)
  ----------- -------------------------------------------------------------------------------------------------------- ----------------- ------------------------- ---------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------ -----------------------------------------------
  [@b30]      15 mL levobupivacaine 0.5%                                                                               29                Lower limb                8 (5)                                                            T8 (T2--12)                       377 (128)                                                          25 (23)                                                       185 (122)                                               62%                                        Hypotension in 18 patients evenly distributed
              15 mL levobupivacaine 0.75%                                                                              30                                          6 (4)                                                            T8 (C6--T11)T7                    460 (111)[a](#tf2-1){ref-type="table-fn"}                          27 (30)                                                       256 (99)                                                                                           
              15 mL bupivacaine 0.5%                                                                                   29                                          7 (4)                                                            (C6--L2)                          345 (107)                                                          17 (7)                                                        192 (74)                                                                                           
  [@b23]      15 (10--18) levobupivacaine 0.5% + CEI levobupivacaine 0.125% 5 mL/h + PCEA 2 mL bolus, lockout 20 min   15                Hip replacement           31 (16)                                                          T7 (T10--T4)                      214 (61)                                                                                                                                                                                 80                                         
              14 (10--18) mL bupivacaine 0.5% + CEI bupivacaine 0.125% 5 mL/h + PCEA 2 mL bolus, lockout 20 min        15                                          25 (19)                                                          T6 (T10--T4)                      213 (53)                                                                                                                                                                                 100                                        
              15 (10--18) mL ropivacaine 0.5% + CEI ropivacaine 0.2% 5 mL/h + PCEA 2 mL bolus, lockout 20 min          15                                          30 (24)                                                          T6 (T10--T4)                      233 (34)                                                                                                                                                                                 60[b](#tf2-2){ref-type="table-fn"}         
  [@b51]      20 mL levobupivacaine 0.75%                                                                              28                Lower abdominal           13 (10--18)                                                      T5--T6                            550.6 (87.6)[c](#tf2-3){ref-type="table-fn"}                       Delayed by levobupivacaine                                    355.4 (83.4)                                            28%                                        82%
              20 mL bupivacaine 0.75%                                                                                  28                                          13 (7--21)                                                       T5--T6                            505.9 (71)                                                                                                                       375.7 (99.2)                                            25%                                        61%
  [@b71]      15 mL levobupivacaine 0.5%                                                                               35                Lower limb                29 (24)                                                                                            185 (77)                                                                                                                         105 (63)                                                33%                                        3%
              15 mL ropivacaine 0.75%                                                                                  30                                          25 (22)                                                                                            201 (75)                                                                                                                         95 (48)                                                 11%                                        12%
  [@b65]      10--15 mL levobupivacaine 0.75%+ CEI levobupivacaine 0.0625% 6 mL/h                                      32                Hip or knee replacement                                                                                                      8.1 (5.0)                                                                                                                        3[e](#tf2-5){ref-type="table-fn"}                       8%[e](#tf2-5){ref-type="table-fn"}         
              10--15 mL levobupivacaine 0.75% + CEI levobupivacaine 0.125% 6 mL/h                                      32                                                                                                                                             9.5 (7.0)                                                                                                                        4                                                       25%                                        
              10--15 mL levobupivacaine 0.75% + CEI levobupivacaine 0.25% 6 mL/h                                       32                                                                                                                                             16.7 (8.3)[d](#tf2-4){ref-type="table-fn"}                                                                                       7                                                       22%                                        
  [@b82]      PCEA 0.1% levobupivacaine + CEI 0.1 mg/h morphine                                                        25                Major abdominal surgery                                                                    T4--T5                                                                                                                                                             4                                                                                                  20%
              PCEA 0.1% ropivacaine + CEI 0.1 mg/h morphine                                                            25                                                                                                           T4--T5                                                                                                                                                             4                                                                                                  20%

p \< 0.05 levobupivacaine 0.75% vs levobupivacaine 0.5% and bupivacaine 0.5%;

p \< 0.05 ropivacaine vs levobupivacaine and bupivacaine;

p = 0.01 levobupivacaine vs bupivacaine;

p \< 0.001 CEI levobupivacaine 0.25% vs levobupivacaine 0.125% and levobupivacaine 0.0625%;

p \< 0.002 CEI levobupivacaine 0.0625% vs levobupivacaine 0.25%.

**Abbreviations:** CEI, continuous epidural infusion; PCEA, patient controlled epidural analgesia.

A better way to control the quality and duration of epidural block with levobupivacaine without excessive motor block and hemodynamic consequences is via continuous epidural infusion. It was shown that a continuous epidural infusion is associated with excellent postoperative analgesia and similar recovery of sensory and motor function after equipotent doses of levobupivacaine, bupivacaine and ropivacaine ([@b23]). The spread, quality and haemodynamic effects are also similar after equal doses of levobupivacaine and ropivacaine, self-administered via postoperative patient-controlled epidural analgesia, but ropivacaine-receiving patients appear to ambulate earlier ([@b82]).

The effective dose of epidural levobupivacaine for continuous postoperative analgesia approaches 15 mg/hour ([@b65]). The concentration of levobupivacaine solution determines the quality of analgesia, ie, 0.25% 6 mL/hour providing better analgesia than same volume more diluted solutions (0.125% and 0.0625%), although some prolongation of the motor blockade may be expected with more concentrated solutions ([@b65]). Dernedde and colleagues encourage the use of large concentration-small volume epidural infusion (ie, 3 mL/h levobupivacaine 0.5% or 2 mL/hour levobupivacaine 0.75%) which provide similar quality of analgesia as the small concentration-large volume infusion (10 mL/hour levobupivacaine 0.15%) but with less motor block and significantly increased hemodynamic stability ([@b35],[@b36], [@b38]). In regards to the mode of delivery, patient-controlled epidural top-ups offer the advantage of equal quality analgesia with that after continuous infusion, but with less consumption of local anesthetic and better motor function ([@b37], [@b38]). Furthermore, the self-administration of levobupivacaine 15 mg either as low concentration large volume (1.5 mg/mL, bolus 3.3 mL, lockout 20 min) or high concentration small volume (5 mg/mL, 1 mL bolus, lockout 20 min) provides an equal quality of analgesia with no difference in the incidence of side effects ([@b37]).

The addition of adjunctive agents (epinephrine, opioids or clonidine) to levobupivacaine in epidural anesthesia and analgesia may increase the duration and quality of analgesia, and further decrease the risk of toxicity. Epinephrine does not significantly influence the onset, spread and duration of sensory and motor epidural block, or the systemic absorption of levobupivacaine ([@b52]). The addition of opioids (fentanyl, morphine) to levobupivacaine improves analgesia compared to levobupivacaine- or opioid-only infusions ([@b53]; [@b31]). It also decreases the risk of local anesthetic toxicity by allowing the use of a small dose levobupivacaine (5--10 mg/hour) and a decline in self-administered analgesia requirements ([@b53]; [@b31]). For example, with combined morphine background infusion (0.1 mg/hour), the effective analgesic dose of levobupivacaine ranges from 8 to 9 mg/hour during the first 24 hours and 7 mg/hour thereafter ([@b82]). Similar improved analgesia and local anesthetic sparing-effect is noticed when clonidine (8 μg/mL) is added to small volume dilute levobupivacaine epidural infusions (0.125% 6 mL/hour) ([@b64]). The motor block tends to be denser with clonidine and some degree of arterial hypotension is expected, rarely of clinical importance ([@b64]).

Peripheral nerve blocks
-----------------------

[Table 3](#tbl3){ref-type="table"} summarizes published studies comparing the characteristics of peripheral nerve blocks with levobupivacaine, bupivacaine and ropivacaine. A sensory and motor block of similar onset (6--10 min) and duration (14--16 hours) followed the administration of an equal dose of levobupivacaine 0.5% or bupivacaine 0.5% in brachial plexus nerve blocks ([@b29]; [@b59]; [@b39]). As expected for larger diameter nerves, the onset time of sciatic nerve block is delayed to approximate 25--30 min, but the average duration remains 14--16 hours ([@b21]; [@b86]). The quality of sensory and motor block appears to be similar in most studies after equal doses of levobupivacaine and bupivacaine ([@b29], [@b21],[@b19], [@b20], [@b25]; [@b86]). Ropivacaine 0.5% gives a less profound motor block than levobupivacaine and bupivacaine ([@b20]; [@b59]). Higher concentrations of levobupivacaine, ie, 0.5%--0.75% speed up the onset, and increase the duration and quality of peripheral nerves blockade ([@b29]; [@b86]; [@b25]). Similar to epidural analgesia, continuing the administration of levobupivacaine via a peripheral nerve block continuous catheter is associated with excellent postoperative analgesia as demonstrated by a significant decline in the postoperative systemic opioids requirements ([@b47]).

###### 

Summary of published research using levobupivacaine in single-shot or continuous infusion in peripheral nerve blocks

  Reference   Dose/concentration                                                                 No. of patients   Type of peripheral nerve block        Onset sensory block ; mean (SD) or median (range), min   Success rate%                           Duration of sensory block; mean (SD) or median (range), min or h   Onset motor block; mean (SD) or median (range), min   Duration of motor block; mean (SD) or median (range), min or h   Satisfactory motor block %                   24 h local anesthetic consumption in continuous infusion; median (range), mL   Postoperative rescue analgesia consumption/24 h; % or n patients
  ----------- ---------------------------------------------------------------------------------- ----------------- ------------------------------------- -------------------------------------------------------- --------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------
  [@b29]      0.4 mL/kg levobupivacaine 0.25%                                                    25                Brachial plexus (supraclavicular)     7 (6)                                                    100%                                    892 (250)                                                          9 (17)                                                847 (246)                                                        68%                                                                                                                         
              0.4 mL/kg levobupivacaine 0.5%                                                     26                                                      6 (5)                                                    92%                                     1039 (317)                                                         5 (5)                                                 1050 (325)                                                       80%                                                                                                                         
              0.4 mL/kg bupivacaine 0.5%                                                         23                                                      8 (8)                                                    91%                                     896 (284)                                                          6 (6)                                                 933 (205)                                                        74%                                                                                                                         
  [@b20]      30 mL levobupivacaine 0.5% + PCA levobupivacaine 0.125% 6 mL/h;                                      Brachial plexus (interscalene)                                                                                                                                                                                                                                  24 h complete regression                                                                                                                                                                     
              2 mL bolus; lockout 15 min                                                         25                                                      20 (15--45)                                              92%                                                                                                                                                              \>90%                                                            80% at 4 h[a](#tf3-1){ref-type="table-fn"}   147 (144--196)                                                                 47%
              30 mL ropivacaine 0.5% + PCA ropivacaine 0.2% 6 mL/h; 2 mL bolus; lockout 15 min   25                                                      20 (10--40)                                              96%                                                                                                                                                              \>90%                                                            60% at 4 h                                   162 (144--248)[b](#tf3-2){ref-type="table-fn"}                                 55%
  [@b59]      45 mL levobupivacaine 0.5%                                                         30                Brachial plexus (axillary)                                                                     57%                                     17.1 (6.5)                                                                                                                                                                                30%                                                                                                                         21
              45 mL bupivacaine 0.5%                                                             30                                                                                                               77% [c](#tf3-3){ref-type="table-fn"}    17.8 (7.2)                                                                                                                                                                                47%                                                                                                                         22
              45 mL ropivacaine 0.5%                                                             30                                                                                                               83% [c](#tf3-3){ref-type="table-fn"}    15.0 (5.4)                                                                                                                                                                                67%d                                                                                                                        26
  [@b39]      40 mL levobupivacaine 0.5%                                                         20                Brachial plexus (axillary)            10 (5--60)                                                                                       1083 (785--1680)                                                   10 (5--120)                                                                                                                                                                                                                                        
              40 mL levobupivacaine 0.5% + clonidine 150 μg                                      20                                                      5 (5--60)                                                                                        1365 (705--2465)                                                   10 (5--180)                                                                                                                                                                                                                                        
              40 mL bupivacaine 0.5%                                                             28                                                      10 (5--60)                                                                                       1063 (600--1310)                                                   10 (5--60)                                                                                                                                                                                                                                         
              40 mL bupivacaine 0.5% + clonidine 150 μg                                          20                                                      10 (5--60)                                                                                       1040 (520--2380)                                                   30 (5--60)                                                                                                                                                                                                                                         
  [@b74]      30 mL levobupivacaine 0.5%                                                         15                Brachial plexus (infraclavicular)     13.46 (1.06)                                                                                     11.40 (2.2) h[e](#tf3-5){ref-type="table-fn"}                      19.33(2.58)                                           42 (0.8) h[e](#tf3-5){ref-type="table-fn"}                                                                                                                                                   
              30 mL ropivacaine 0.75%                                                            15                                                      14.20 (1.17)                                                                                     10.26 (1.38) h                                                     20.20 (2.39)f                                         8.33 (1.48) h                                                                                                                                                                                
  [@b19]      20 mL levobupivacaine 0.5%                                                         25                Sciatic nerve                         30 (5--60)                                               92%                                     16 (8--24)                                                                                                               13 (4--22)                                                                                                                                                                                   12%
              20 mL ropivacaine 0.5%                                                             25                                                      15 (5--60)                                               96%                                     16 (8--24)                                                                                                               12 (6--20)                                                                                                                                                                                   16%
  [@b24]      30 mL levobupivacaine 0.5% + levobupivacaine 0.2% 6 mL/h                           20                Continous sciatic nerve (popliteal)   34 (17)                                                                                                                                                                                                                   24 h complete regression 35%                                                                                  150(144--200)                                                                  5.5%
              30 mL levobupivacaine 0.5% + levobupivacaine 0.125% 6 mL/h                         20                                                      32 (15)                                                                                                                                                                                                                   95% [g](#tf3-7){ref-type="table-fn"}                                                                          148(144--164)                                                                  11%
              30 mL ropivacaine 0.5% + ropivacaine 0.2% 6 mL/h                                   20                                                      28 (15)                                                                                                                                                                                                                   85% [g](#tf3-7){ref-type="table-fn"}                                                                          148(144--228)                                                                  27%
  [@b73]      30 mL levobupivacaine 0.5%                                                         40                Lumbar + sciatic (30/10 mL)           10.63 (1.39)                                                                                     15.52 (2.78)                                                                                                             12.17 (1.69)                                                                                                                                                                                 
              30 mL ropivacaine 0.75%                                                            40                Lumbar + sciatic (30/10 mL)           17.15 (2.87)[h](#tf3-8){ref-type="table-fn"}                                                     14.80 (1.91)                                                                                                             12.30 (1.60)                                                                                                                                                                                 
  [@b21]      20 mL levobupivacaine 0.5%                                                         15                Sciatic nerve                         32 (5)                                                   94%                                     814 (96)                                                                                                                 716 (80)                                                                                                                                                                                     
              20 mL bupivacaine 0.5%                                                             15                                                      35 (5)                                                   94%                                     790 (110)                                                                                                                761 (112)                                                                                                                                                                                    
  [@b25]      20 mL levobupivacaine 0.5%                                                         15                Sciatic nerve                         30 (5--60)[i](#tf3-9){ref-type="table-fn"}               75%                                     16 (13--20)[j](#tf3-10){ref-type="table-fn"}                                                                                                                                                                                                                                                                          8[k](#tf3-11){ref-type="table-fn"}
              20 mL levobupivacaine 0.75%                                                        15                                                      5 (5--40)                                                100%                                    18 (15--19)[j](#tf3-10){ref-type="table-fn"}                                                                                                                                                                                                                                                                          3
              20 mL ropivacaine 0.75%                                                            15                                                      20 (5--50)                                               87%                                     13 (11--14)                                                                                                                                                                                                                                                                                                           9[k](#tf3-11){ref-type="table-fn"}
  [@b86]      20 mL levobupivacaine 0.5%                                                         20                3-in-1 block                          24 (18--30)                                              80% [l](#tf3-12){ref-type="table-fn"}   1001 (844--1158)[m](#tf3-13){ref-type="table-fn"}                                                                                                                                                                                                                                                                     
              20 mL levobupivacaine 0.25%                                                        20                                                      30 (23--36)                                              45%                                     707 (551--863)                                                                                                                                                                                                                                                                                                        
              20 mL bupivacaine 0.5%                                                             20                                                      27 (20--33)                                              80% [l](#tf3-12){ref-type="table-fn"}   1053 (802--1304)[m](#tf3-13){ref-type="table-fn"}                                                                                                                                                                                                                                                                     

p = 0.003 levobupivacaine vs ropivacaine;

p = 0.02 ropivacaine vs levobupivacaine;

p \< 0.01 ropivacaine and bupivacaine vs levobupivacaine;

p \< 0.01 ropivacaine vs levobupivacaine and bupivacaine;

p \< 0.05 levobupivacaine vs ropivacaine;

p \< 0.05 ropivacaine vs levobupivacaine;

p = 0.0005 ropivacaine 0.2% and levobupivacaine 0.125% vs levobupivacaine 0.2%;

p \< 0.05 ropivacaine vs levobupivacaine;

p = 0.02 levobupivacaine 0.5% vs levobupivacaine 0.75%;

p = 0.002 levobupivacaine 0.5% and levobupivacaine 0.75% vs ropivacaine 0.75%;

p = 0.05 levobupivacaine 0.5% and ropivacaine 0.75% vs levobupivacaine 0.75%;

p = 0.02 levobupivacaine 0.5% and bupivacaine 0.5% vs levobupivacaine 0.25%;

p = 0.01 levobupivacaine 0.5% and bupivacaine 0.5% vs levobupivacaine 0.25%.

Adding adjunctive analgesics such as epinephrine, clonidine or opioids to local anesthetic are also used to increase the quality of analgesia and improve safety by decreasing the requirements of levobupivacaine. The long duration of sensory and motor peripheral blockade after levobupivacaine of approximate 14--16 hours diminish the clinical importance of adding epinephrine to levobupivacaine. However, epinephrine may help decrease the potential for systemic toxicity in case of overdose by decreasing systemic absorption through vasoconstriction or by signaling the accidental intravascular injection. The addition of clonidine to levobupivacaine in axillary plexus or psoas compartment was not followed by any significant effect on block's characteristics and postoperative analgesic requirements ([@b39]; [@b61]). In contrast, our group found a significant decrease in postoperative systemic morphine use when clonidine was added to levobupivacaine in continuous paravertebral nerve block ([@b11]). Similarly, we found that the addition of fentanyl to levobupivacaine is also followed by excellent analgesia as demonstrated by a significant decrease in rescue morphine analgesia. Furthermore, we demonstrated that clonidine and fentanyl had a strong local anesthetic sparing effect, as the concentration of levobupivacaine (0.05%) used for continuous infusion was the lowest ever used in paravertebral block ([@b11]).

Levobupivacaine in obstetric anesthesia and analgesia
=====================================================

Spinal anesthesia for caesarean section
---------------------------------------

The concept of pharmacological equipotency of levobupivacaine and bupivacaine was challenged in several dose-finding studies in obstetric patients receiving spinal anesthesia for caesarean section. For example, Khaw and colleagues found that levobupivacaine is 38% less potent than bupivacaine, with an ED50 and ED95 values of 9.3 and 13.6 mg vs 6.8 and 9.8 mg, respectively ([@b49]). Parpaglioni and colleagues estimated a similar ED95 levobupivacaine of 12.56 mg, whereas the ED95 ropivacaine was 15.97 mg ([@b70]). The above potency hierarchy ie, bupivacaine \>levobupivacaine \> ropivacaine was confirmed in clinical studies in caesarean section patients ([@b41]; [@b14]). Based on these studies and our own experience, we recommend that levobupivacaine 12.5--13.5 mg should be used for successful spinal anesthesia for caesarean section. A test dose of 10 mg levobupivacaine is sufficient to confirm at 5 min the accidental intrathecal placement of an epidural-intended catheter ([@b15]).

Analgesia for labor
-------------------

Minimum effective local anesthetic concentration (MLAC) studies using a combined spinal-epidural analgesia technique (CSE) for labor also confirm the potency arrangement bupivacaine \>levobupivacaine \>ropivacaiane for spinal sensory block ([@b16]). However, the above hierarchy is not so clear in regards to epidural only analgesia for labor. Up-and-down sequential allocation studies in patients receiving epidural analgesia for labor pain show that levobupivacaine and bupivacaine on one side ([@b60]), and levobupivacaine and ropivacaine on the other side ([@b77]; [@b4]) are equipotent. One would reasonably assume that the three local anesthetics are equipotent. Intriguingly however, in other similar design studies ([@b76]; [@b17]), ropivacaine was found to be 40% to 50% less potent than bupivacaine. The minimum effective local anesthetic concentration of levobupivacaine for motor block (MMLAC) is significantly greater than that of bupivacaine indicating that levobupivacaine is less potent at motor block than bupivacaine when administered in epidural analgesia for labor ([@b54]).

The relative potency of the three most commonly used drugs in obstetric anesthesia remains to be further elucidated, but the current evidence from MLAC and MMLAC studies suggest a potency hierarchy of bupivacaine \>levobupivacaine \>opivacaine. However, the epidural and spinal MLAC or MMLAC studies estimate the concentration at which only 50% of laboring patients will have adequate pain control with minimal motor block. In clinical practice, anesthetists are inclined to administer larger doses of local anesthetic to ensure adequate pain relief in the majority of patients. Because of the variety of doses and adjunctive analgesics combinations used in clinical studies ([Table 4](#tbl4){ref-type="table"}), the rank of order established by the MLAC studies is not always easy to corroborate ([@b9]; [@b28]; [@b78]; [@b57]; [@b85]).

###### 

Summary of clinical studies of epidural (with its versions ie single bolus, continuous infusion or patient-controlled epidural analgesia) and combined spinal-epidural analgesia in labour.

  Reference   Dose/concentration                                                     No. Subjects   Anesthetic technique                 Onset time of sensory block, mean (SD) or median (range), min   Maximum sensory dermatome level   Duration of sensory block mean (SD) or median (range), min   Successful sensory block (% patients)   Modified Bromage \> 0 (% patients)      Maternal arterial hypotension (% patients)
  ----------- ---------------------------------------------------------------------- -------------- ------------------------------------ --------------------------------------------------------------- --------------------------------- ------------------------------------------------------------ --------------------------------------- --------------------------------------- --------------------------------------------
  [@b9]       10 mL levobupivacaine 0.25%                                            68             10 mL epidural bolus +               12 (5--39)                                                      T8                                49 (3--129)                                                  85%                                     16%                                     11%
              10 mL bupivacaine 0.25%                                                69             10 mL top-ups                        12 (2--50)                                                      T9                                51 (7--157)                                                  91%                                     17%                                     7%
  [@b28]      10 mL levobupivacaine 0.25%                                            38             10 mL epidural bolus +                                                                               Similar                                                                                        43.3%                                   Less motor block with levobupivacaine   
              10 mL bupivacaine 0.25%                                                42             CEI 0.125% 12 mL/h +                                                                                                                                                                                43.7%                                                                           
                                                                                                    10 mL 0.25% top-ups                                                                                                                                                                                                                                                                 
  [@b85]      10 mL levobupivacaine 0.2%                                             20             10 mL epidural bolus                                                                                 T8 (6--10)                        90.50 (31.72)                                                100%                                    20%                                     0
              10 mL ropivacaine 0.2%                                                 20                                                                                                                  T8 (6--10)                        103.30 (37.52)                                               100%                                    30%                                     0
  [@b78]      15 mL levobupivacaine 0.1% with fentanyl 2 μg/mL                       28             15 mL epidural bolus;                38 (19--51)                                                     T6 (3--11)                        34 (25--50)                                                                                          32%                                     32%
              15 mL ropivacaine 0.1% with fentanyl 2 μg/mL                           26             PCEA 5 mL; lockout 5 min             30 (15--45)                                                     T8 (4--11)                        35 (20--37)                                                                                          30%                                     50%
  [@b57]      2.5 mg levobupivacaine                                                 20             CSE                                  5                                                               T4 (1--9)                         51.5 (3.4)                                                   100%                                    0%                                      5%
              2.5 mg bupivacaine                                                     20                                                  5                                                               T3 (1--8)                         76.3 (5.9)[a](#tf4-1){ref-type="table-fn"}                   100%                                    25%[a](#tf4-1){ref-type="table-fn"}     5%
              2.5 mg ropivacaine                                                     20                                                  5                                                               T4 (1--9)                         52.6 (4.0)                                                   100%                                    10%                                     0%
  [@b58]      2.5 mg levobupivacaine                                                 20             CSE; CEI levobupivacaine                                                                             T4 (1--9)                         361 (66)                                                     43.8%                                   15%                                     0%
              2.5 mg levobupivacaine + 25 μg fentanyl                                20             0.125% with fentanyl 2 μg/mL                                                                         T3 (1--8)                         530 (65)[b](#tf4-2){ref-type="table-fn"}                     87.5%[b](#tf4-2){ref-type="table-fn"}   25%                                     15%
  [@b26]      2.5 mg levobupivacaine + fentanyl 25 μg                                20             CSE                                  15                                                              T4 (2--10)                        101.4 (26.64)                                                95%                                     75%c                                    10%
              1.25 mg levobupivacaine + fentanyl 12.5 μg                             20                                                  15                                                              T4 (3--10)                        90.6 (28.03)                                                 100%                                    25%                                     5%
  [@b84]      Levobupivacaine 0.125% + sufentanyl 2.5 μg/mL + 1:800000 epinephrine   34             CEI 10 mL/h + 10 mL mixture top-up                                                                                                                                                                  88% [d](#tf4-4){ref-type="table-fn"}    50%                                     6%
              Levobupivacaine 0.125% + sufentanyl 2.5 μg/mL                          33                                                                                                                                                                                                                 66%                                     27%                                     9%

p \< 0.05 bupivacaine vs levobupivacaine and ropivacaine;

p \< 0.05 levobupivacaine and fentanyl vs levobupivacaine only;

p \< 0.01 levobupivacaine 2.5 mg with fentanyl 25 μg vs half dose of each;

p \< 0.05 epinephrine group vs the other group.

**Abbreviations:** CEI, continuous epidural infusion; CSE, combined spinal-epidural; PCEA, patient-controlled epidural analgesia.

[Table 4](#tbl4){ref-type="table"} also shows the results of several studies using levobupivacaine combined with opioids with or without epinephrine in epidural or CSE analgesia in labor. In particular, the addition of fentanyl to levobupivacaine prolongs the duration and increases the success rate of the sensory block after intrathecal administration in a CSE analgesia technique ([@b58]). A local anesthetic sparing effect of fentanyl is also demonstrated as intrathecal levobupivacaine 1.25 mg with fentanyl 12.5 μg was followed by effective analgesia with less motor block compared with a double dose of each drug ([@b26]). The addition of epinephrine to a mixture of levobupivacaine and opioid increased the success rate of sensory block but appeared to also increase the frequency of motor blockade ([@b84]).

In our experience, using an epidural bolus of 10 mL levobupivacaine 0.2%--0.25% followed by epidural infusions or top-ups of low concentrations levobupivacaine (ie, 0.1%--0.125%) combined with opioids based on institutionally designed protocols, provides the same good quality labor analgesia as bupivacaine, but possibly with less motor block. A combined spinal-epidural technique with intrathecal levobupivacaine 1.2--2.5 mg combined with small dose opioid (eg, fentanyl 12.5--25 μg) provides excellent prolonged sensory block with minimum motor blockade.
